Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland

Journal of Mammary Gland Biology and Neoplasia

Volumn 2, Issue 2, 1997, Pages 187-198

  Carraway, Kermit L ^a   Carothers Carraway, Coralie A ^a   Carraway III, Kermit L ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Heterodimerization; Ligand; Mammary development; Mammary tumors; Signaling; Tyrosine receptor kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ANIMAL; BREAST; BREAST TUMOR; DIMERIZATION; FEMALE; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; UDDER;

ANIMALS; BREAST; BREAST NEOPLASMS; DIMERIZATION; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 0031107209     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026360032602     Document Type: Article

References (79)

1. D. Medina (1996). The mammary gland: A unique organ for the study of development and tumorigenesis. J. Mam. Gland Biol. Neoplasia 1:5-19.
2. Y. J. Topper and C. S. Freeman (1980). Multiple hormone interactions in the developmental biology of the mammary gland. Physiol. Rev. 60:1049-1106.
3. T. Oka, M. Yoshimura, S. Lavandero, K. Wada, and Y. Ohba (1991). Control of growth and differentiation of the mammary gland by growth factors. J. Dairy Sci. 74:2788-2800.
4. C. D. Roskelly and M. J. Bissell (1995). Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracellular matrix regulates mammary epithelial cell function. Biochem. Cell Biol. 73:391-397.
5. C. D. Roskelly, A. Srebow, and M. J. Bissell (1995). A hierarchy of ECM-mediated signaling regulates tissue-specific gene expression. Curr. Opin. Cell Biol. 7:736-747.
6. C. J. Wilde and W. L. Hurley (1996). Animal models for the study of milk secretion. J. Mam. Gland Biol. Neoplasia 1:123-134.
7. R. D. Cardiff (1996). The biology of mammary transgenes: Five rules. J. Mam. Gland Biol. Neoplasia 1:61-73.
8. W. G. Cance and E. T. Liu (1995). Protein kinases in human breast cancer. Breast Cancer Res. Treat. 35:105-114.
9. C. A. C. Carraway and K. L. Carraway (1996). Interactions of membrane receptors and cell signaling systems with the cytoskeleton. In J. E. Hesketh and I. F. Pryme, (eds.), Treatise on the Cytoskeleton, Vol. 2, JAI Press, Inc., Greenwich, Connecticut pp. 207-238.
10. H. S. Earp, T. L. Dawson, X. Li, and H. Yu (1995). Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35:115-132.
11. K. L. Carraway, III and L. C. Cantley (1994). A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5-8.
12. M. H. Kraus, W. Issing, T. Miki, N. C. Popescu, and S. A. Aaronson (1989). Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 86:9193-9197.
13. G. D. Plowman, G. S. Whitney, M. G. Neubauer, J. M. Green, V. L. McDonald, G. J. Todaro, and M. Shoyab (1990). Molecular cloning and expression of an additional EGF receptor-related gene. Proc. Natl. Acad. Sci. U.S.A. 87:4905-4909.
14. G. D. Plowman, J.-M. Culouscou, G. S. Withney, J. M. Green, G. W. Carlton, L. Foy, M. G. Neubauer, and M. Shoyab (1993). Ligand-specific activation of HER4/p180erB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750.
15. E. Peles and Y. Yarden (1993). Neu and its ligands: From an oncogene to neural factors. BioEssays 15:815-824.
16. K. L. Carraway and C. A. C. Carraway (1995). Signaling, mitogenesis and the cytoskeleton: where the action is. BioEssays 17:171-175.
17. W. J. Gullick (1996). The c-erbB3/HER3 receptor in human cancer. Cancer Surv. 27:339-349.
18. erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U.S.A. 91:8132-8136.
19. G. Carpenter and S. Cohen (1990). Epidermal growth factor. J. Biol. Chem. 265:7709-7712.
20. J. Schlessinger (1988). Signal transduction by allosteric receptor dimerization. Trends Biochem. Sci. 13:443-447.
21. erbB4 receptor. J. Biol. Chem. 268:18407-18410.
22. E. Peles, S. S. Bacus, R. A. Koski, H. S. Lu, D. Wen, S. G. Ogden, R. B. Levy, and Y. Yarden (1992). Isolation of the Neu/ HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216.
23. D. Wen, E. Peles, R. Cupples, S. V. Suggs, S. S. Bacus, Y. Luo, G. Trail, S. Hu, S. M. Silbiger, R. B. Levy, R. A. Koski, H.S. Lu, and Y. Yarden (1992). Neu differentiation factor-a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559-572.
24. W. E. Holmes, M. X. Sliwkowski, R. W. Akita, W. J. Henzel, J. Lee, J. W. Park, D. Yansura, N. Abadi, H. Raab, G. D. Lewis, H. M. Shepard, W.-K. Kuang, W. I. Wood, D. V. Goeddel, and R. L. Vandlen (1992). Identification of heregulin, a specific activator of p185(erbB2). Science 256:1205-1210.
25. E. Peles, R. Ben-Levy, E. Tzahar, N. Liu, D. Wen, and Y. Yarden (1993). Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12:961-971.
26. erbB4. Nature 366:473-475.
27. W. C. Dougall, X. L. Qian, and M. I. Greene (1993). Interaction of Neu/p185 and EGF receptor tyrosine kinases implications for cellular transformation and tumor therapy. J. Cell. Biochem. 53:61-73.
28. D. J. Riese II, T. M. van Raaij, G. D. Plowman, G. C. Andrews, and D. F. Stern (1995). The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15:5770-5776.
29. K. L Carraway III, M. X. Sliwkowski, R. Akita, J. V. Platko, P. M. Guy, A. Nuijens, A. J. Diamonti, R. L. Vandlen, L. C. Cantley, and R. A. Cerione (1994). The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 269:14303-14306.
30. R. Pinkas-Karmarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. J. Ratzkin, M. Sela, and Y. Yarden (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:2452-2467.
31. M. X. Sliwkowski, G. Schaefer, R. W. Akita, J. A. Lofgren, V. D. Fitzpatrick, A. Nuijens, B. M. Fendly, R. A. Cerione, R. L. Vandlen, and K. L. Carraway, III (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:14661-14665.
32. E. Tzahar, G. Levkowitz, D. Karunagaran, L. Yi, E. Peles, S. Lavi, D. Chang, N. Liu, A. Yayon, D. Wen, and Y. Yarden (1994). ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor heregulin isoforms. J. Biol. Chem. 269:25226-25233.
33. C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich (1994). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14:4267-4275.
34. D. J. Riese II, Y. Bermingham, T. M. van Raaij, S. Buckley, G. D. Plowman, and D. F. Stern (1996). Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12:345-353.
35. X. Chen, G. Levkowitz, E. Tzahar, D. Karunagaran, S. Lavi, N. Ben-Baruch, O. Leitner, B. J. Ratzkin, S. S. Bacus, and Y. Yarden (1996). An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem. 271:7620-7629.
36. R. R. Beerli, D. Graus-Porta, K. Woods-Cock, X. Chen, Y. Yarden, and N. E. Hynes (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15:6496-6505.
37. D. Karunagaran, E. Tzahar, R. R. Beerli, X. Chen, D. Graus-Porta, B. J. Ratzkin, R. Seger, N. E. Hynes, and Y. Yarden (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15:254-264.
38. S. C. Harrison (1996). Peptide-surface association: The case of PDZ and PTB domains. Cell 86:341-343.
39. S. A. Prigent and W. J. Gullick (1994). Identification of c-ereB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using a EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831-2841.
40. P. Fedi, J. H. Pierce, P. P. Di Fiore, and M. H. Kraus (1994). Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase Cγ or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol. Cell. Biol. 14:492-500.
41. S. P. Soltoff, K. L. Carraway III, S. A. Prigent, W. G. Gullick, and L. C. Cantley (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14:3550-3558.
42. K. L. Carraway, III, S. P. Soltoff, A. J. Diamonti, and L. C. Cantley (1995). Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270:7111-7116.
43. M. Alimandi, A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aronson, P. P. Di Fiore, and M. H. Kraus ( 1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821.
44. M. A. Avila, J. A. Velasco, C. Cho, R. Lupu, D. Wen, and V. Notario (1995). Hyperactive autocrine loop mediated by a NDF-related factor in neoplastic hamster embryo fibroblasts expressing an activated cph oncogene. Oncogene 10:963-971.
45. B. D. Cohen, J. M. Green, L. Foy, and H. P. Fell (1996). HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J. Biol. Chem. 271:4813-4818.
46. K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, and S.K. Yoshinaga (1996). Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271:3884-3890.
47. D. C. Gamett, T. Greene, A. R. Wagreich, H.-H. Kim, J. G. Koland, and R. A. Cerione (1995). Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85. J. Biol. Chem. 270: 19022-19027.
48. cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J. Biol. Chem. 271:563-567.
49. J. N. Ihle (1996). STATs: Signal transducers and activators of transcription. Cell 84:331-334.
50. S. A. Prigent, T. S. Pillay, K. S. Ravichandran, and W. J. Gullick (1995). Binding of Shc to the NPXY motif is mediated by its N-terminal domain. J. Biol. Chem. 270:22097-22100.
51. J.-M. Culouscou, G. W. Carlton, and A. Aruffo (1995). HER4 receptor activation and phophorylation of Shc proteins by recombinant heregulin-Fc fusion proteins. J. Biol. Chem. 270:12857-12863.
52. D. Graus-Porta, R. R. Beerli, and N. E. Hynes (1995). Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15:1182-1191.
53. B. M. Marte, D. Graus-Porta, M. Jeschke, D. Fabbro, N. E. Hynes, and D. Taverna (1995). NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 10:167-175.
54. T. Horan, J. Wen, T. Arakawa, N. Liu, D. Brankow, S. Hu, B. Ratzkin, and J. S. Philo (1995). Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J. Biol. Chem. 270:24604-24608.
55. D. Wen, S. V. Suggs, D. Karunagaran, N. Liu, R. L. Cupples, Y. Luo, A. M. Janssen, N. Ben-Baruch, D. B. Trollinger, V. L. Jacobsen, S.-Y. Meng, H. S. Lu, S. Hu, D. Chang, W. Yang, D. Yanigahara, R. A. Koski, and Y. Yarden (1994). Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol. 14:1909-1919.
56. M. Marikovsky, S. Lavi, R. Pinkas-Kramarski, D. Karunagaran, N. Liu, D. Wen, and Y. Yarden (1995). ErbB3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10:1403-1411.
57. M. Katoh, Y. Yazaki, T. Sugimura, and M. Terada (1993). c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem. Biophys. Res. Commun. 192:1189-1197.
58. J. Baulida, M. H. Kraus, M. Alimandi, P. P. di Fiore, and G. Carpenter (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:5251-5257.
59. K. L. Carraway, III, E. Rossi, P. M. Guy, D. Lorenzo, M. E. Carvajal, R. A. Cerione, C. A. C. Carraway, and K. L. Carraway. (Undated). An intramembrane ErbB2/Neu ligand expressed in a metastatic mammary tumor, (manuscript submitted).
60. neu with microfilaments via a large glycoprotein complex in mammary carcinoma microvilli. Evidence for a microfilament-associated signal transduction particle. J. Biol. Chem. 268:5582-5587.
61. M. A. Marchionni, A. D. J. Goodearl, M. S. Chen, O. Bermingham-McDonogh, C. Kirk, M. Hendricks, F. Danehy, D. Misumi, J. Sudhalter, K. Kobayashi, D. Wroblewski, C. Lynch, M. Baldassare, I. Hiles, J. B. Davis, J. J. Hsuan, N. F. Totty, M. Otsu, R. N. McBurney, M. D. Waterfield, P. Stroobant, and D. Gwynne (1993). Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312-318.
62. D. L. Falls, K. M. Rosen, G. Corfas, W. S. Lane, and G. D. Fischbach (1993). ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family. Cell 72:801-815.
63. K. L. Carraway, III (1995). Involvement of the neuregulins and their receptors in cardiac and neural development. BioEssays 18:263-266.
64. R. Kramer, N. Bucay, D. J. Kane, L. E. Martin, J. E. Tarpley, and L. E. Theil (1996). Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc. Natl. Acad. Sci. U.S.A. 93:4833-4838.
65. K. L. Carraway, III and S. J. Burden (1995). Neuregulins and their receptors. Curr. Opin. Neurobiol. 5:606-612.
66. N. M. Shah, M. A. Marchionni, I. Isaacs, P. Stroobant, and D. J. Anderson (1994). Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77:349-360.
67. erbB2 Proc. Natl. Acad. Sci. U.S.A. 92:1431-1435.
68. N. Altiok, J.-L. Bessereau, and J.-P. Changeux (1995). ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate. EMBO J. 14:4258-4266.
69. L. M. Moscoso, G. C. Chu, M. Gautam, P. G. Noakes, J. P. Merlie, and J. R. Sanes (1995). Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/ heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Develop. Biol. 172: 158-169.
70. J. A. Loeb and G. D. Fischbach (1995). ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain. J. Cell Biol. 130:127-135.
71. Y. Yang, E. Spitzer, D. Meyer, M. Sachs, C. Niemann, G. Hartmann, K. M. Weidner, C. Birchmeier, and W. Birchmeier (1995). Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J. Cell Biol. 131:215-226.
72. T. W. Grunt, M. Saceda, M. B. Martin, R. Lupu, E. Dittrich, G. Krupitza, H. Harant, H. Huber, and C. Dittrich (1995). Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. Int. J. Cancer 63:560-567.
73. T. G. Ram, K. E. Kokeny, C. A. Dilts, and S. P. Ethier (1995). Mitogenic activity of Neu Differentiation Factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. J. Cell. Physiol. 163:589-596.
74. erbB2. Mol. Carcin. 15: 227-238.
75. erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Diff. 7:551-561.
76. N. E. Hynes and D. F. Stern (1995). The biology of erB-2/neu/ HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
77. G. Gasparini, W. J. Gullick, S. Maluta, P. D. Palma, O. Caffo, E. Leonardi, P. Boracchi, F. Pozza, N. R. Lemoine, and P. Bevilacqua (1994). c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma-an immunocytochemical study. Eur. J. Cancer 30A:16-22.
78. N. R. Lemoine, D. M. Barnes, D. P. Hollywood, C. M. Hughes, P. Smith, E. Dublin, S. A. Prigent, W. J. Gullick, and H. C. Hurst (1992), Expression of the ERBB3 gene product in breast cancer. Br. J. Cancer 66:1116-1121.
79. S. S. Bacus, C. R. Zelnick, G. Plowman, and Y. Yarden (1994). Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implications for tumor biology and clinical behavior. Am J. Clin. Pathol. 102:S13-S24.